Introduction
============

The structural similarity between methylenetetrahydrofolate (MTHF) **2H** ^[@cit1]--[@cit5]^ and Thauer\'s hydrogenase **3H** ^[@cit6]^ has led us to investigate imidazolidines **1H** as model compounds for the reactivity of these fascinating biomolecules ([Fig. 1](#fig1){ref-type="fig"}).

![Structural relationship between imidazolidines **1H**, methylenetetrahydrofolate (MTHF) **2H**, and Thauer\'s hydrogenase **3H**. Different structural formulae resulting from different N-protonation positions can be found in the literature for **2H**. The structure presented in this figure is the one most commonly used.^[@cit1]^](c6sc04314c-f1){#fig1}

A type of reactivity shared by **2H** and **3H** is the transfer of negatively charged "hydridic" hydrogen leading to the very stable cationic species **\[2\]^+^** and **\[3\]^+^**.

In addition to its function as a hydride donor, MTHF is involved in several other biochemical pathways including folate-dependent DNA methylation, purine, pyrimidine, and amino acid syntheses, as well as the methylation of homocysteine to methionine. MTHF is also the precursor to 5-methyltetrahydrofolate, an important intermediate in its own right.^[@cit1]--[@cit5]^

The recent discovery that the hydride donor system **2H**/**\[2\]^+^** acts as a photobiological cofactor in the light-activated repair enzyme DNA photolyase^[@cit5]^ demonstrates that MTHF offers significant surprises even after more than sixty years of extensive research. For comprehensive reviews on Thauer\'s hydrogenase **3H** see [@cit6].

Results
=======

Reduction of halogenated hydrocarbons
-------------------------------------

During our initial studies,^[@cit7]^ we were surprised to find that imidazolidines **1H** (R: methyl, *tert*-butyl)^[@cit8]^ are unstable in chloroform and resemble many organometallic compounds and hydrido complexes in this respect. A closer examination revealed that the reason for this instability was the reduction of chloroform to dichloromethane by **1H** acting as a hydride donor. By-product of the reduction is the salt **\[1\]^+^Cl^--^** ([Scheme 1](#sch1){ref-type="fig"}). We now report that this type of reduction is remarkably general and allows for the dehalogenation of a wide variety of halogenated hydrocarbons including those of toxicological, environmental, and pharmacological significance.

![Reduction of carbon--halogen bonds R′--X by imidazolidine **1H** (R: *tert*-butyl).](c6sc04314c-s1){#sch1}

To further explore the scope of the reductive dehalogenation, the reactivity of **1H** towards a series of chloromethanes and bromomethanes was investigated. With the exceptions of dichloromethane, chloromethane, and bromomethane, all chlorine- and bromine-substituted methanes are reduced by **1H**. The reductions occur at room temperature, but the time required for a complete conversion ranges from weeks for chloroform to only minutes for bromoform and carbon tetrabromide. Reactions of **1H** with allyl bromide and ethyl 2-bromoacetate resulted in the formation of complex product mixtures. Details about the reaction as well as the compatibility of functional groups are the subject of on-going studies and will be reported in a separate publication.

The nature of the employed solvent (ethanol, hexanes), an excess of **1H**, or an excess of the halogenated methane do not significantly influence the reaction rates. Remarkably, the dehalogenation reactions are not inhibited by air or moisture.

An excess of the halogenated hydrocarbon and prolonged reaction times lead to further oxidation of **\[1\]^+^X^--^** to **\[4\]^+^X^--^** ([Scheme 1](#sch1){ref-type="fig"}).

The unsaturated imidazoline analogues of **1H** were previously found to be incompatible with biomimetic conditions due to their high sensitivity towards moisture.^[@cit7c]^ To investigate if the lack of reduction observed for some of the halogenated substrates is due to thermodynamic reasons or is the result of kinetic factors the reaction energies Δ*G*° for the halide--hydride exchange were determined by quantum chemical calculations ([Table 1](#tab1){ref-type="table"}).^[@cit9]^ A computational solvation model for water was added to simulate biological conditions (see Methods).^[@cit10]^

###### Computational free energies Δ*G*° (CBS-QB3 level,^[@cit11]^ H~2~O-SMD solvent model,^[@cit10]^ kcal mol^--1^) for the reductions of selected halomethanes (A → B) by **1H** (R: *tert*-butyl)

  A           B           X:Cl     X:Br
  ----------- ----------- -------- --------
  CX~4~       CHX~3~      --48.3   --37.9
  CHX~3~      CH~2~X~2~   --44.3   --39.1
  CH~2~X~2~   CH~3~X      --41.0   --36.5
  CH~3~X      CH~4~       --39.8   --29.3
  PhX         PhH         --35.9   --31.3

The calculated energies show that all reactions are thermodynamically favourable. The lack of reactivity observed for bromomethane, chloromethane, and dichloromethane is accordingly only the result of low reaction rates.

The observed reaction rates show no correspondence to the calculated reaction energies Δ*G*° but closely match the order of decreasing carbon--halogen bond energies (CBS-QB3 level, kcal mol^--1^): CH~3~Br (77.1), CHCl~3~ (77.0), CH~2~Br~2~ (71.7), CCl~4~ (71.9), CHBr~3~ (65.3), CBr~4~ (62.9).

To test for the ability of **1H** to reduce polybrominated commercial flame retardants,^[@cit12]^ 1,3,5-tribromobenzene was investigated ([Scheme 2](#sch2){ref-type="fig"}). Dehalogenation to 1,3-dibromobenzene occurred within minutes, even at room temperature, although the total reduction to benzene requires prolonged heating at 150 °C.

![Reaction of imidazolidines **1H** with 1,3,5-tribromobenzene.](c6sc04314c-s2){#sch2}

As carbon--halogen bonds are found in many medicinal drugs, the dehalogenation reactions observed for the MTHF model **1H** may well occur *in vivo* with MTHF itself, with obvious implications for drug metabolism as well as toxicology.

As a test case, the reaction of the inhalation anaesthetic halothane, CF~3~CH(Br)Cl, with **1H** was examined ([Scheme 3](#sch3){ref-type="fig"}). Dehalogenation was observed (NMR) at room temperature within minutes with 2-chloro-1,1,1-trifluoroethane, CF~3~CH~2~Cl,^[@cit13]^ being formed as the sole reduction product.

![Reaction of imidazolidines **1H** with 2-bromo-2-chloro-1,1,1-trifluoroethane (halothane).](c6sc04314c-s3){#sch3}

The high reactivity and selectivity observed suggests that **1H** may become a new substitute for the tin hydrides^[@cit18]^ and hydrosilanes^[@cit19]^ previously used for selective debrominations.

Discussion
==========

While *in vivo* studies will inevitably be required to further study the biochemical implications of these findings, the reactivity of **1H** does suggest that MTHF-dependent biochemical pathways are likely to be disrupted by halogenated hydrocarbons. It is of interest to note in this context that MTHF is the precursor to 5-methyltetrahydrofolate -- a compound under current investigation for the treatment of depression and schizophrenia.^[@cit4]^

The reported reductive dehalogenation reactions are highly unusual for a simple, neutral, and stable organic molecule like **1H**, but have precedence in the fascinating reactivity of dehalohydrogenases.^[@cit15]^

Dehalohydrogenases have been isolated from a variety of microorganisms^[@cit14]--[@cit16]^ and have attracted great interest for their ability to reduce a number of highly toxic, halogenated hydrocarbons like the notorious 2,3,5,6-tetrachlorodibenzodioxin.^[@cit16]^ A notable difference between our system **1H** and dehalohydrogenases reported to date is that the latter require metal cofactors like iron-sulphur proteins or cobalamines.^[@cit17]^ The fact that dehalohydrogenase-type activity is possible with metal-free folate models **1H** suggests that metal-free dehalohydrogenases can exist as well.

Methods
=======

Quantum chemical calculations
-----------------------------

All calculations were carried out with Gaussian 09, Revision D.01.^[@cit9]^ The energies were obtained from full optimizations with the CBS-QB3 method^[@cit11]^ and the SMD solvent model^[@cit10]^ for water. Minima were verified by the absence of virtual frequencies.

Starting materials
------------------

The imidazolines **1H** (R: *tert*-butyl, methyl, *para*-methyphenyl) were prepared from the respective 1,2-diaminoethanes as described elsewhere.^[@cit7]^ Halothane and 1,3,5-tribromobenzene were purchased from Sigma-Aldrich Inc.

Reduction of halocarbons
------------------------

To the best of our knowledge the only previously reported reduction of a halogenated hydrocarbon by a MTHF analogue is that of CCl~4~.^[@cit8]^ Reductions were carried out with a slight excess of the imidazolidines **1H** (1.1 equivalent per reducible halogen). In nonpolar solvents like hexanes or diethyl ether, the onset of the reduction is indicated by the appearance of turbidity with subsequent precipitation of the salts **\[1\]^+^X^--^**. Control experiments in polar solvents or under inert gas (99.995% argon) with degassed materials did not show noticeably different reaction rates or products. For the less reactive aryl halides and chloromethanes, heating was required to drive the reaction to completion. The progress of the reductions was monitored by NMR and GC-MS. After completion of the reaction, the salts were isolated by filtration under inert gas, washed with diethyl ether, and dried *in vacuo*. Yield 85--95%. Traces of **\[4\]^+^X^--^** could be removed from **\[1\]^+^X^--^** by recrystallization from 95% ethanol.

Reduction of halothane
----------------------

To retain the highly volatile product 2-chloro-1,1,1-trifluoroethane (bp +6 °C)^[@cit13a]^ the reduction of halothane was monitored in a flame-sealed NMR tube.

Spectroscopic data
------------------

### 2-Bromo-2-chloro-1,1,1-trifluoroethane (halothane)

^1^H-NMR (600 MHz, C~6~D~6~): *δ* 4.58 \[q, ^3^ *J*(^1^H,^19^F) = 5.4 Hz\]. ^13^C-NMR (600 MHz, C~6~D~6~): *δ* 50.2 \[q, ^2^ *J*(^13^C,^19^F) = 40.9 Hz, CHClBr\], 121.6 \[q, ^1^ *J*(^13^C,^19^F) = 278.0 Hz, CF~3~\]. ^19^F-NMR (600 MHz, C~6~D~6~ *vs.* CFCl~3~): *δ* --76.1 \[d, ^3^ *J*(^1^H,^19^F) = 5.3 Hz\].

### 2-Chloro-1,1,1-trifluoroethane

^1^H-NMR (600 MHz, C~6~D~6~): *δ* 2.78 \[q, ^3^ *J*(^1^H,^19^F) = 8.5 Hz\]. ^13^C-NMR (600 MHz, C~6~D~6~): *δ* 40.1 \[q, ^2^ *J*(^13^C,^19^F) = 37.7 Hz, CH~2~\], 123.1 \[q, ^1^ *J*(^13^C,^19^F) = 275.7 Hz, CF~3~\]. ^19^F-NMR (600 MHz, C~6~D~6~ *vs.* CFCl~3~): *δ* --71.6 \[t, ^3^ *J*(^1^H,^19^F) = 8.5 Hz\].

### 1,3,5-Tribromobenzene

^1^H-NMR (400 MHz, CDCl~3~): *δ* 7.61 \[s\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 123.4 \[C-2,4,6\], 133.0 \[C-1,3,5\]. GC-MS: *t* ~r~ = 10.28 min *m*/*z* (rel. int%): 314(100)\[M^+^\], 235(30), 156(15), 74(32).

### 1,3-Dibromobenzene

^1^H-NMR (400 MHz, CDCl~3~): *δ* 7.67 \[m\], 7.43 \[m\], 7.11 \[m\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 123.1 \[C-1,3\], 130.3 \[C-4,6\], 131.2 \[C-5\], 134.2 \[C-2\]. GC-MS: *t* ~r~ = 8.57 min *m*/*z* (rel. int%): 236(100)\[M^+^\], 155(41), 75(32).

### 1,3-Di-*tert*-butylimidazolidinium chloride

Colourless crystals, mp 202--203 °C (from chloroform). ^1^H-NMR (400 MHz, CDCl~3~): *δ* 1.55 \[18H, s, C(CH~3~)~3~\], 4.05 \[4H, s, CH~2~CH~2~\], 8.85 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 28.2 \[C(CH~3~)~3~\], 45.3 \[CH~2~CH~2~\], 57.2 \[C(CH~3~)~3~\], 154.1 \[N~2~CH^+^\].

### 1,3-Di-*tert*-butylimidazolidinium bromide

Colourless crystals, mp 230--231 °C (dec.) (from chloroform). ^1^H-NMR (400 MHz, CDCl~3~): *δ* 1.56 \[18H, s, C(CH~3~)~3~\], 4.10 \[4H, s, CH~2~CH~2~\], 8.46 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 28.3 \[C(CH~3~)~3~\], 45.5 \[CH~2~CH~2~\], 57.2 \[C(CH~3~)~3~\], 153.1 \[N~2~CH^+^\].

### 1,3-Di-*tert*-butylimidazolium chloride

Colourless crystals, mp 209--210 °C (from chloroform). ^1^H-NMR (400 MHz, CDCl~3~): *δ* 1.80 \[18H, s, C(CH~3~)~3~\], 7.54 \[4H, s, HC0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000CH\], 10.54 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 30.3 \[s, C(CH~3~)~3~\], 60.8 \[C(CH~3~)~3~\], 119.7 \[HCCH\], 134.5 \[N~2~CH^+^\].

### 1,3-Di-*tert*-butylimidazolium bromide

Colourless crystals, mp 219--220 °C (from chloroform). ^1^H-NMR (400 MHz, CDCl~3~): *δ* 1.85 \[18H, s, C(CH~3~)~3~\], 7.39 \[4H, s, HCCH\], 10.37 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 30.4 \[C(CH~3~)~3~\], 61.2 \[C(CH~3~)~3~\], 118.9 \[HCCH\], 135.2 \[N~2~CH^+^\].

### 1,3-Dimethylimidazolidinium bromide

Colourless crystals, mp 189--191 °C (from chloroform). ^1^H-NMR (400 MHz, CDCl~3~): *δ* 3.35 \[18H, s, NCH~3~\], 4.01 \[4H, s, NCH~2~\], 9.54 \[1H, s, N~2~CH^+^\]. ^1^H-NMR (400 MHz, DMSO-D~6~): *δ* 3.08 \[18H, s, NCH~3~\], 3.85 \[4H, s, NCH~2~\], 8.41 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 35.2 \[NCH~3~\], 50.9 \[CH~2~CH~2~\], 159.4 \[N~2~CH^+^\]. ^13^C-NMR (400 MHz, DMSO-D~6~): *δ* 34.1 \[NCH~3~\], 50.2 \[CH~2~CH~2~\], 158.3 \[N~2~CH^+^\].

### 1,3-Di-*para*-methylphenylimidazolidine

Colourless crystals, mp 157--158 °C. ^1^H-NMR (400 MHz, CDCl~3~): *δ* 2.28 \[6H, s, C--CH~3~\], 3.59 \[4H, s, CH~2~CH~2~\], 4.60 \[2H, s, N~2~CH~2~\], 6.58 \[4H, d, ^3^ *J* = 8.5 Hz, *meta*-CH\], 7.10 \[4H, d, ^3^ *J* = 8.5 Hz, *ortho*-CH\]. ^13^C-NMR (400 MHz, CDCl~3~): *δ* 20.4, \[C--CH~3~\], 46.8 \[CH~2~CH~2~\], 66.4 \[N~2~CH~2~\], 112.5, 126.7, 129.8, 144.4. GC-MS: *t* ~r~ = 17.9 min *m*/*z* (rel. int%): 252(72)\[M^+^\], 251(100), 133(39), 118(16), 105(81), 91(30), 65(10).

### 1,3-Di-*para*-methylphenylimidazolium bromide

Colourless crystals, mp 292--293 °C (from methanol). ^1^H-NMR (400 MHz, DMSO-D~6~): *δ* 2.35 \[6H, s, C--CH~3~\], 4.56 \[4H, s, CH~2~CH~2~\], 7.36 \[4H, d, ^3^ *J* = 8.4 Hz, *meta*-CH\], 7.53 \[4H, d, ^3^ *J* = 8.4 Hz, *ortho*-CH\], 9.89 \[1H, s, N~2~CH^+^\]. ^13^C-NMR (400 MHz, DMSO-D~6~): *δ* 20.3, \[C--CH~3~\], 48.2 \[CH~2~CH~2~\], 118.1, 129.9, 133.6, 136.4, 150.9 \[N~2~CH^+^\].

Conclusions
===========

Our observation that dehalohydrogenase activity is possible with a simple, metal-free MTHF model **1H** suggests that metal-free dehalohydrogenases may likewise exist.

The ready synthetic accessibility of the model compounds **1H** as well as their dehalogenation activity in the presence of air and moisture suggest their use for the remediation of toxic, halogenated hydrocarbons. The reactions suggest that halocarbons are likely to act as endocrinological disruptors of folate dependent pathways.
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